found lost and/or changed compared to 15% (5/32) for TCRG, 3% (1/32) for TCRD and 3% (1/32) of patients for DJH gene rearrangements (Figure 1) . Besides, our data were comparable with those previously published for childhood T-ALL using the BIOMED-2 multiplex TCRB PCR assay, 11 confirming the reliability of our findings. Nevertheless, some discrepancies concerning the frequency of complete Vb-Jb and incomplete Db-Jb gene rearrangements found at diagnosis (72 and 52%, respectively) could be due to the different primer set utilized for detection of clonal TCRB rearrangements.
Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia Imatinib mesylate has been shown to selectively inhibit the tyrosine kinase domain of the oncogenic bcr-abl fusion protein in vitro and using animal models. Thereafter, impressive responses have been reported by several phases II and one phase III studies in patients with chronic myelogenous leukemia (CML) at all stages. Particularly, complete hematological responses and also early cytogenetic responses were observed for most patients with chronic phase disease. 1 Considering these goals, as well as progression to advanced phase disease, superiority of imatinib was demonstrated in comparison to previous treatments (interferon alfa (IFNa) and combination of IFNa and cytarabine) and it has become the first-line therapy for the majority of patients with newly diagnosed chronic phase CML. 2 A recent update of the randomized phase III IRIS trial confirmed the better results of imatinib, median follow-up being still short (42 months). 3 Indeed, efficiency of the targeted therapy was observed at the molecular level, with a rate of bcr-abl transcript becoming very low, even undetectable for some patients. However, despite complete sustained molecular response, discontinuation of imatinib is currently not recom-mended, as relapse may occur. 4 This address the important issue of imatinib long-term side effects, particularly for younger patients. Giving current available data, treatment with imatinib is generally well tolerated, the risk of severe adverse event being low. 5 Side effects most commonly include mild to moderate edema, nausea and vomiting, diarrhea, muscle cramps, and cutaneous reactions. Hepatic transaminase level elevations and myelosuppression occur less frequently and resolve with interruption of imatinib therapy. However, with almost 5 years experience with imatinib there is still some concern about the long-term side effects. We recently encountered in our institution several patients with CML who were treated with imatinib and in whom second neoplasms developed. This observation prompted a search for the occurrence of second neoplasms in our cohort of 189 patients treated with imatinib.
From June 1999 to November 2004, 189 adult patients were treated with imatinib in our institution. Median age was 60 years (range 21-83) including 11% patients less than 40 years, 69% between 40 and 69 years and 21% more than 70 years. Of the patients, 75 were females (40%) and 114 males (60%). Median follow-up time of CML was 5 years (1 month-18 years) and median exposition time to imatinib was 2.6 years (1 week-5 years).
Among the 189 adult patients treated with imatinib, six patients developed a second malignancy while on imatinib therapy. All six patients (Table 1a) had received prior interferonbased regimen. Duration of these treatments was 5-96 months. Reasons for switching to imatinib were mainly relapse or resistance with interferon. Imatinib was given at initial dose of 400 mg for four patients, two patients received 600 mg for accelerated phase. All six patients but one achieved major (less than 35% of Ph positive cells) or complete cytogenetic response. Duration of imatinib therapy was 27-46 months. Second malignancies occurred from 33 to 110 months from CML diagnosis, duration from start of imatinib therapy being 8-36 months. In four patients urogenital tract was concerned including three with prostate cancer (Patients 1, 2 and 3 in Tables 1a and b), age being less than 70 years. Among the three other patients, a 73-year-old man (Patient 4) developed an invasive transitional cell carcinoma of the urothelium from the top of the urinary bladder corresponding to a minimal T2 staging in the TNM classification. It was revealed by hematuria, 22 months after initiation of imatinib, and previous smoking may also have contributed to this malignancy. Another 60-year-old woman (Patient 5) without risk factor underwent investigations for episodes of rectal bleeding, being at 21 months of imatinib exposure. The diagnosis of well-differenciated adenocarcinoma from the sigmoid was made, with limited spreading to the middle layers of the wall, corresponding to a Stage I in the NCI classification. For the last 65-year-old woman (Patient 6), an isolated inguinal adenopathy was detected 29 months after the initiation of imatinib and histopathology concluded to a metastatic squamous cell carcinoma involvement. However, despite extensive investigations, primary site of the tumor could never be determined and the patient experienced unfortunately a disseminated relapse shortly after termination of radiotherapy and chemotherapy.
Specific treatment and outcome for the second cancer are summarized in Table 1b .
The cumulative incidence of second cancer (all categories) and prostate cancer in our CML patients are 3.2% (95% CI: 1.2-6.6%) and 1.6% (95% CI: 0.3-4.6%), respectively. Person-years at risk were calculated from the date of diagnosis of CML to the date of last patient contact, date of death or date of diagnosis of second cancer, which ever came first. Thus, the accumulated person-years at risk are 1096 for the whole cohort and 627 for men. The observed ratio of secondary cancer among the whole cohort and prostate cancer among men are 547.4 per 100 000 person-years and 478.5 per 100.000 person-years, respectively. The estimations of average annual prostate cancer incidence rates in France specific for 40-69 years of age range from 35.0 to 110.6 per 100 000 men. 6, 7 Accordingly, within the limitations of the number of patients which are enrolled in this retrospective study, the total number of cases of cancer could be in accordance with the incidence of cancer in the French population; however, the excess frequency of prostate cancer is at least four times higher than expected.
We then reviewed the follow-up records of the 36 patients from our center who never received imatinib and were prospectively included between 1988 and 2001 in clinical trials [8] [9] [10] testing IFNa therapy with or without cytarabine. Median age was 61 years (range 31-80); 10 were female and 26 male. The median follow-up was 7.5 years. None of these patients developed urinary bladder or prostate tumors. In all, two male patients experienced a second tumor: one had a melanoma after 7 years of interferon therapy and one died from a pancreatic carcinoma 14 months after the diagnosis. No female patient experienced second tumor. Similar analysis was performed in the whole population of patients included in a French CML 91 trial. 9 From January 1991 to May 1996, 731 patients (age p70 years) with a CML Ph þ chronic phase were randomized. All patients were given simultaneously hydroxyurea (HU) at a daily dose of 50 mg/kg and IFN a2b at a starting dose of 5.10 6 IU/m 2 /day for induction. Patients included in the IFNa-cytarabine group received the same induction regimen and in addition, low-dose cytarabine was administered at a dose of 20 mg/m 2 /10 days per month 2 weeks after the beginning of the induction regimen. As of January 2001, and before any patient received imatinib for whatever reason, the median follow-up was 6 years. In all, 11 patients had their clinical course complicated by a second malignancy (1.5%), however; none of these patients developed urinary bladder or prostate tumors.
In this study, we found that in a cohort of patients who received IFNa followed by imatinib as therapy for CML, the incidence of second malignancies, particularly of prostate, was increased substantially above that expected. Whether the observed increased incidence of second malignancies is greater than expected in a similar population of CML patients treated with standard chemotherapy or stem cell transplantation is an important issue which cannot be answered, because of the lack of such a control population. However, reports from the literature suggest that increased incidence of such malignancies were not recorded.
Out of 1036 patients, who underwent transplantation (BMT) in 45 European centers cooperating in the EBMT, 53 cases of new malignant disorder were recorded. 11 The most frequent tumors were carcinomas of the skin; basal-cell and squamouscell carcinomas; tumors of the oral cavity; carcinomas of the uterus, including carcinoma in situ of the cervix; breast cancer; thyroid gland cancer; and brain tumors. In 208 patients transplanted for CML (3.8%) eight tumors were recorded. In this series of patients the risk of solid tumor after transplantation for acute myelogenous leukemia or aplastic anemia was higher (6.3 and 6.7, respectively) as compared to CML patients.
Bhatia et al 12 analyzed 2129 patients who had undergone BMT for hematologic malignancies at their center between 1976 and 1998. Of the patients, 29 developed solid cancers after BMT, which represents a two-fold increase in risk compared with a comparable normal population. The estimated cumulative probability for development of a solid cancer was 6.1% at 10 years. None of these second solid cancers were urinary bladder or prostate tumors. Among the 392 CML patients, six were diagnosed with cervix cancer or from the oral cavity. Finally, there are no reports from the literature suggesting an increase incidence of second malignancies after treatment with HU for CML. For example, the German Group conducted a randomized trial (n ¼ 376 CML newly diagnosed patients) to compare the combination of IFNa and HU vs HU monotherapy. 13 Although the trial did not specifically focuses on the risk of second malignancies, the number of second malignancies reported was low (three (2.5%) patients in the IFNa/HU and five (2.4%) in the HU arms died from a second malignancy, respectively).
Since our study was in progress, an investigator notification for imatinib was sent to all physicians in charge of patients included in clinical trials. A preclinical study in rats of a 2-year oral carcinogenicity of imatinib at doses of 15, 30, and 60 mg/kg was completed. A statistically significant increase in renal benign and malignant tumors, in urinary bladder benign tumors and in benign and malignant tumors of the preputial/clitoral gland was noted. However, dose of imatinib in rats represented 0.5-4.14 Â human daily exposure (based on AUC) to imatinib at the dose of 400 mg/day. At present, the incidence rate of cancers of the kidney, urinary bladder, and prostate observed in patients treated with imatinib in clinical trials sponsored by Novartis does not differ from the incidence rate of such tumors in the general population. However, a growing number of patients are currently treated out of trials based on the drug marketing approval. A systematic report to the Health Authorities of adverse such as second tumors is probably less frequent for patients not included in clinical trials. Thus, the exact frequency of such event could be underestimated.
At the present time, our observation could be related to a particular recruitment and it is uncertain whether the subsequent solid tumor is the result of imatinib therapy, whether it is related to previous IFN therapy, or whether it is a cumulative effect of both exposures.
Hence, further long-term analyses are necessary with patients receiving imatinib as front-line therapy or after a previous exposure to IFN, to conclude about an increased incidence of therapy-related second malignancies. Many myeloproliferative disorders (MPDs) are due to constitutively activated tyrosine kinases (TK) that induce cell survival and proliferation. Chronic myeloid leukaemia (CML), which is associated with BCR-ABL fusion, is the most frequent typical MPD. Fusions of PDGFRB and FGFR1 with various partners have been found in atypical CML, chronic myelomonocytic leukaemia and other, unclassifiable, MPDs. A PCM1-JAK2 fusion was recently characterised in MPDs. 1, 2 Mutation of the JAK2 kinase is frequent in polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis. 3 We report here the characterization of four new cases of t(8;9)(p22;p24) with PCM1-JAK2 fusion. The main characteristics of the four patients are reported on Table 1 , along with those from two studies.
1,2 All patients were adult male patients except C2, who was a 12-year-old girl presenting with multiple vertebral tumours and abnormal cells in the bone marrow (BM).
